SARFEZ
Live / Registered — Registered — Section 8 accepted (as of 29 May 2024)
What this means for you
Registered since 01 Jan 2019. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 01 Jan 2029: the §8 & §9 renewal).
Record
- Serial number
- 87549883
- Registration number
- 5644543
- Mark type
- Word mark
- Filed
- 31 Jul 2017
- Published for opposition
- 20 Feb 2018
- Registered
- 01 Jan 2019
- Next maintenance filing
- §8 & §9 renewal, due by 01 Jan 2029 (grace period to 01 Jul 2029)
Goods and services
- Class 005 — Pharmaceuticals: Cardiorenal medication
Owner
- Sarfez Pharmaceuticals Inc, Vienna, VA, US
- Sarfez Pharmaceuticals Inc, Vienna, VA, US
- Sarfez Pharmaceuticals Inc, Vienna, VA, US
Prosecution history
- 29 May 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 29 May 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 28 May 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 22 Jan 2024 — TEAS SECTION 8 RECEIVED
- 01 Jan 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 01 Jan 2019 — REGISTERED-PRINCIPAL REGISTER
- 30 Nov 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 29 Nov 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Nov 2018 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Nov 2018 — NON-FINAL ACTION E-MAILED
- 14 Nov 2018 — SU - NON-FINAL ACTION - WRITTEN
- 10 Oct 2018 — STATEMENT OF USE PROCESSING COMPLETE
- 14 Sept 2018 — USE AMENDMENT FILED
- 10 Oct 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 14 Sept 2018 — TEAS STATEMENT OF USE RECEIVED